Revolution Medicines (RVMD) Cash from Financing Activities (2019 - 2026)

Revolution Medicines' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $238.7 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 27216.25% year-over-year to $238.7 million; the TTM figure through Mar 2026 stood at $859.4 million (down 10.43% YoY), while the FY2025 annual figure was $621.5 million, down 35.22% from the prior year.
• Cash from Financing Activities was $238.7 million for Q1 2026 at Revolution Medicines, down from $365.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $873.8 million in Q4 2024 to a low of -$1.6 million in Q3 2025.
• Historically, Cash from Financing Activities has averaged $197.1 million across 5 years, with a median of $64.6 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 106196.72% in 2023, then tumbled 102.06% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $51.4 million in 2022, then jumped by 1534.16% to $839.4 million in 2023, then advanced by 4.1% to $873.8 million in 2024, then slumped by 58.15% to $365.7 million in 2025, then tumbled by 34.71% to $238.7 million in 2026.
• The last three Cash from Financing Activities figures came in at $238.7 million (Q1 2026), $365.7 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.